Bio-immune cellular therapy is the most advanced therapy of its kind. Throughout the extraction, manipulation and culture of specific cells from the immune system it is now possible to provide a high concentration of cells that can improve, enhance, reinforce and balance the immune response needed to fight disease. Their proven uses array from autoimmune disorders, chronic infections, HIV to Cancer.

Dendritic Cell (DC) therapy represents a new and promising immunotherapeutic approach for treatment of advanced cancer as well as for secondary prevention of cancer.

Recent breakthroughs have shown that tumor-associated antigens can be used to vaccinate patients and that the dendritic cell is a potent blood cell able to present such antigens and stimulate the native immune system.

T-cell Modulators do not cure anything but work to make a “smarter” immune system so that it is the body itself eliminating disease. They are therefore vital in developing the strategies of the immune system against cancer.

T-cell Modulators are immunomodulators in the sense that they do not force a global but specific and adequate response to malignant cells.

T-cell Modulators store ‘chemical photographs’ of the malignant cells in the body itself and transmit that information to the cells dedicated to combating the disease in the body where they are introduced.

T-cell Modulators contains several immunoactive components that have been shown to act synergistically in raising Dendritic and NK function.

Vitamin B-17 is natural and powerful anti-tumor agent found in over 1,200 plants, and is best known for its ability to prevent metastases without collateral damage to healthy normal cells.

Vitamin B-17 is effective in reducing tumor related pain and increasing the survivability of late stage critical patients. It is best known for its ability to prevent metastases in all types of cancers.

As early as 1974, Vitamin B-17 was being used intravenously and through treatment of thousands of patients, the Angeles Functional Oncology team has found the most impactful method of Laetrile treatment.

The principle is that cancer cells react more sensitively to the effects of excessive heat than normal cells.

Also, tumors have an impaired ability to adapt their blood circulation to the effects of high temperatures and thus hyperthermia can cause a reduction of blood flow to a tumor. In addition, heat at this level pushes cancer cells toward acidosis (decreased cellular pH) which decreases the cells´ viability and ability to spread. It also activates the immune system, causing increased immune surveillance.

The combination of immunotherapy with hyperthermia for treating cancer, however, is a particularly intriguing notion, as significant clinical effects of hyperthermia have been attributed to the immune system. The accepted view of the cancer-host immune interface is that tumors possess unique antigens that can be recognized by the immune system. After antigen uptake at tumor sites, APCs have the ability to create a robust response by entering lymphoid compartments and programming lymphocytes. Following generation and expansion to large numbers, cytotoxic lymphocytes then traffic to tumor sites for targeted cell killing.